Share on facebook Share on Twitter Share on Google Plus Share This
Back to Results

Examining the Effects of Medicincation and Hormone Therapy on PSA

Title Prostate Cancer - Examining the effects of Bicalutamide with or without MK-2206 on PSA
Therapeutic Area
Principal Investigator Paul Mathew, MD
Min Age 18 Years
Gender Male
Contact Jodi Jensen, RN
More Information


This study is being done to compare the effects, good and/or bad, of MK-2206 and Bicalutamide (a type of hormonal therapy), versus Bicalutamide alone on lowering PSA. In this study, subjects will receive either MK-2206 combined with Bicalutamide OR Bicalutamide alone. If they  are selected to receive Bicalutamide alone, they will not be eligible to receive MK-2206 as part of this study. The study will also evaluate the safety of the Bicalutamide and MK-2206 combination therapy.

Study Details

Inclusion Criteria

  • Must have histologically confirmed diagnosis of prostate cancer. 
  • Must have had previous treatment with definitive surgery or radiation therapy or cryoablation.

Exclusion Criteria

  • Must not have GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease. 
  • Must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Study Requirements

Participants will be randomized into either Group A or Group B. Group A participants will be observed for the first three cycles of the study. Then, they will be given only Bicalutamide. Group B participants will be given the study drug, MK-2206, for the first three cycles. After cycle 3 and beyond, they will be given the MK-2206 with Bicalutamide. All participants in the study will have blood tests, physical exams, and body scans.
Nurse navigators for cancer patients at Tufts Medical Center.

Are you interested in learning more about this clinical trial?

Send us a message and we'll get back to you with more information.

Request information